Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for people with rare and debilitating diseases such as Lambert-Eaton myasthenic syndrome (LEMS), epilepsy, and Duchenne muscular dystrophy (DMD). Catalyst is dedicated to advancing cutting-edge science and improving the lives of patients through its clinical research pipeline, approved products, and compassionate use programs. The company actively engages in environmental, social, and governance (ESG) responsibilities and strives for social responsibility in all its endeavors.